Antiproliferative activity of interferon gamma in superficial bladder cancer

Anticancer Research

Volumn 19, Issue 5 C, 1999, Pages 4529-4533

  Stavropoulos, Nickolaos E ^a,b   Ioachim, Elli ^a   Pappa, Lina ^a   Hastazeris, Konstantinos ^a   Agnantis, Niki J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

Author keywords

Bladder cancer; Interferon gamma; Ki67; Proliferating cell nuclear antigen

Indexed keywords

CYCLINE; GAMMA INTERFERON; KI 67 ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; HUMANS; INTERFERON-GAMMA, RECOMBINANT; KI-67 ANTIGEN; PROLIFERATING CELL NUCLEAR ANTIGEN; URINARY BLADDER NEOPLASMS;

EID: 0033452652     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Paucker K, Cantell K, Henle W: Quantitative studies on viral interference in suspended cells. III. Effect of interfering viruses and interferon on the growth rate of cells: Virology 17: 324-334, 1962.
2. Gresser I: Autoimmune effects of interferon. Adv Cancer Res 16: 97-140, 1972.
3. Taylor-Papadimitriou J: Effects of interferons on cell gro,wth and function. In: Interferon (Gresser I, ed.) New York, Academic Press 1980, 2, pp 13-46.
4. Brouty-Boye D: Inhibitory effect of interferons on cell multiplication. Lymphokine Rep 1: 99-112, 1980.
5. Crease AA, Bartholomew JC, Merigan TC: Role of G0-G1 arrest in the inhibition of tumour cell growth by interferon. Proc Natl Acad Sci USA 77: 1471-1475, 1980.
6. Ottesen SS, Ahrenkiel V and Kieler J: Recombinant human interferon gamma exerts an anti-proliferative effect and modulates the expression of human leukocyte antigens A,B,C and DR in human urothelial cell lines. Cancer Immunol Immunother 31: 93-98, 1990.
7. Van Moorselaar RJA, Beniers AJMC, Hendriks Ben Th, Van der Meide PH, Schellekens H, Debruyne FMJ,r and Schalken JA. In vivo antiproliferative effects of gamma-interferon and tumour necrosis factor alpha in a rat renal cell carcinoma model system. J Urol 143: 1247-1251, 1990.
8. Visakorpi Tapio: Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. J Pathol 168: 7-13, 1992.
9. Lipponen PK, Eskelimen MJ: Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value. Br J Cancer 66: 1,171-176, 1992.
10. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, Barnes DM, Gillet CE, Camplejohn R, Dover R, Waseem NH and Lane DP: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 62: 285-294, 1990.
11. Mathews MB, Bernstein RM, Franza BR Jr, Garrels JI: Identity of the proliferating cell nuclear antigen and cyclin. Nature 309: 374-376, 1984.
12. Prelich G, Tan CK, Kotsura M, Mathews MB, So AG, Downey KM, Stillman B: Functional identity of proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 326: 517-520, 1987.
13. Waseem NH, Lane DP: Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci 96: 121-129, 1990.
14. Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell population. Int J Cancer 31: 13-20, 1983.
15. Schwarting R, Gerdes J, Niehus J, Jaeschke L, Stein H: Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods 90: 65-70, 1986.
16. Mellon K, Neal DE, Robinson MC, March C, Wright C: Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67. Br J Urol 66: 281-285, 1990.
17. Mulder AH, Van Hootegem JCSP, Sylvester R: Prognostic factors in bladder carcinoma: Histological parameters and expression of a cell cycle related nuclear antigen (Ki67). J Pathol 166: 37-45, 1992.
18. Okamura K, Miyake K, Koshikawa K, Asai J: Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki67. J Urol 144: 875-878, 1990.
19. Tsujihashi H, Nakanishi A, Matsuda H, Uejima S, Kurita T: Cell proliferation of human bladder tumours determined by BrdUrd and Ki67 immunostaining. J Urol 145: 846-849, 1991.
20. Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, Kitsiou E, Stefanaki S and Agnantis N: Growth fractions in bladder cancer defined by Ki67: Association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 72: 736-739, 1993.
21. Hattori K, Uchida K, Akaza H, Koiso K, Nemoto R, Harada M: Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. Br J Urol 75: 162-166, 1995.
22. Scopelitou A, Hadjiyannakis M, Dimopoulos D, Kamina S, Krikoni O, Alexopoulou V, Rigas C, Agnantis NJ: p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. Eur Urol 31: 464-471, 1997.
23. Asakura T, Takano Y, Iki M, Suwa Y, Nogushi S, Kubota Y and Masuda M: Prognostic value of Ki67 for recurrence and progression of superficial bladder cancer. J Urol 158: 385-388, 1997.
24. Geboers ADH, van Bergen TNLM and Oosterlinck W: Gamma interferon in the therapeutic and prophylactic treatment of superficial bladder tumours. J Urol 137: 276A, 1987.
25. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981.
26. Hawkyard SJ, Jackson AM, James K, Prescott S, Smyth JF, Chisholm GD: The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol 147: 1399-1403, 1992.
27. Krüger S and Müller H: Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 75: 480-484, 1995.
28. Asakura T, Takano Y, Iki Mf, Suwa Y, Noguchi S, Kubota Y, Masuda M: Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 158: 385-388, 1997.
29. Cohen MB, Waldman FM, Carrol PR, Kerchmann R, Chew K, Mayal BH: Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 24: 772-778, 1993.
30. Jakse G, Marth C, Zechner J, Daxenblichler G: Antiproliferative effect of Hu-interferon-gamma in 647V and J82 bladder carcinoma cell lines. Urol Res 16: 403-405, 1988.
31. Shuai K, Liao J, Song MM: Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Statl. Mol Cell Biol 16: 9 4932-4941, 1996.
32. Creasy AA, Bartholomew JC, Merigan TC Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77:3, 1471-1475, 1980.
33. Stavropoulos NE, Ioachim E, Pavlidis N, Pappa L, Kalomiris P, Agnantis NJ: Local immune response after intravesical interferon gamma in superficial bladder cancer. Br J Urol 81: 875-879, 1998.
34. Prescott S, James K, Hargreave TB, Chisholm GD: Radioimmunoassay detection of interferon-gamma in urine after intravesical BCG therapy. J Urol 144: 1248-1251, 1990.